The Lancet Haematology : Impact Factor & More
eISSN: 2352-3026pISSN: 2352-3026
Share this on:
Key Metrics
CiteScore 
19.9
SNIP
5
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on The Lancet Haematology
The Lancet Haematology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ELSEVIER SCI LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2014 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Haematology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in The Lancet Haematology
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.
- 1 May 2026
- The Lancet. Haematology
Patient selection and treatment sequencing in RESMAIN.
- 1 Apr 2026
- The Lancet. Haematology
Balancing the benefits and risks of rebalancing coagulation in haemophilia.
- 1 Apr 2026
- The Lancet. Haematology
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
- 1 Apr 2026
- The Lancet. Haematology
From diagnosis to equitable care in bleeding disorders.
- 1 Apr 2026
- The Lancet. Haematology
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
- 1 Apr 2026
- The Lancet. Haematology
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.
- 1 May 2026
- The Lancet. Haematology
Patient selection and treatment sequencing in RESMAIN.
- 1 Apr 2026
- The Lancet. Haematology
Balancing the benefits and risks of rebalancing coagulation in haemophilia.
- 1 Apr 2026
- The Lancet. Haematology
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
- 1 Apr 2026
- The Lancet. Haematology
From diagnosis to equitable care in bleeding disorders.
- 1 Apr 2026
- The Lancet. Haematology
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
- 1 Apr 2026
- The Lancet. Haematology
FAQs on The Lancet Haematology
How long has The Lancet Haematology been actively publishing? 
What is the publishing frequency of The Lancet Haematology?
How many articles did The Lancet Haematology publish last year?
What is the eISSN & pISSN for The Lancet Haematology?
What is Citescore for The Lancet Haematology?
What is SNIP score for The Lancet Haematology?
Who is the publisher of The Lancet Haematology?
